. Generation of mice expressing Bcor that cannot bind to BcL6. (a) Strategy for making a conditional knockout allele for Bcor exon 4 by homologous recombination in embryonic stem cells. FRT recombinase was used to remove the PGK-Neo cassette. (b) Efficient deletion of Bcor exon 4 in hematopoietic cells detected by genomic PCR. Deletion of Bcor exon 4 in Cre-ERT;Bcor fl/y PB Mac1 + Gr-1 + myeloid cells from recipient mice repopulated with Cre-ERT;Bcor fl/y hematopoietic cells before and 4 wk after tamoxifen treatment. Floxed, floxed Bcor allele; Δ, floxed Bcor allele after the removal of Somatic mutations in BCOR or BCO RL1 have also been identified in 9.3% of patients with aplastic anemia and correlated with a better response to immunosuppressive therapy and longer and higher rates of overall and progression-free survival (Yoshizato et al., 2015) . Furthermore, BCOR mutations have been found in retinoblastoma, bone sarcoma, and clear cell sarcoma of the kidney (Pierron et al., 2012; Zhang et al., 2012a; Kelsey, 2015) .
BCOR has been shown to restrict myeloid proliferation and differentiation in culture using conditional loss-of-function alleles of Bcor in which exons 9 and 10 are missing. This mutant Bcor allele generates a truncated protein that lacks the region required for the interaction with PCGF1, a core component of PRC1.1, and mimics some of the pathogenic mutations observed in patients with OFCD and hematological malignancies (Cao et al., 2016) . The tumor suppressor function of Bcor has recently been confirmed in vivo using Myc-driven lymphomagenesis in mice (Lefebure et al., 2017) . However, limited information is available on its role in hematopoiesis and hematological malignancies. In the present study, we investigated the function of BCOR using mice expressing variant BCOR, which cannot bind to BCL6, and revealed a critical role for BCOR in restricting transformation of hematopoietic cells.
rEsuLts And dIscussIon Generation of mice expressing Bcor that cannot bind to BcL6
To understand the physiological role of BCOR as a BCL6 corepressor, we generated mice harboring a Bcor fl mutation in which exon 4 encoding the BCL6-binding site (Ghetu et al., 2008) was floxed ( Fig. 1 a) , and then crossed Bcor fl mice with Rosa26::Cre-ERT (Cre-ERT) mice. We transplanted BM cells from Cre-ERT control (WT) and Bcor fl/y ;Cre-ERT CD45.2 male mice (Bcor is located on the X chromosome) without competitor cells into lethally irradiated CD45.1 recipient mice and deleted Bcor exon 4 by intraperitoneal injections of tamoxifen at 4 wk posttransplantation. We hereafter refer to the recipient mice reconstituted with WT and Bcor ΔE4/y cells as WT and Bcor ΔE4/y mice, respectively. We confirmed the efficient deletion of Bcor exon 4 in hematopoietic cells from Bcor ΔE4/y mice by genomic PCR (Fig. 1 b) . RNA-sequence analysis of lineage-marker (Lin) − Sca-1 + c-Kit + (LSK) hematopoietic stem and progenitor cells (HSPCs) revealed the specific deletion of Bcor exon 4 ( Fig. 1 c) . Bcor lacking exon 4 generates a short form of BCOR protein (BCOR ΔE4 ) that lacks the BCL6 binding site but still retains the binding site for PCGF1, a component of PRC1.1 (Fig. 1 d) . Western blot analysis detected a short form of BCOR in thymocytes from Bcor ΔE4/y mice (Fig. 1 e) . To test physical interactions between BCL6 and BCOR ΔE4 , we cotransfected 293T cells with plasmids encoding HA-tagged BCL6 and Flag-tagged BCOR and performed immunoprecipitation. Full-length BCOR readily coimmunoprecipitated with BCL6, but BCOR ΔE4 scarcely did. In contrast, full-length BCOR and BCOR ΔE4 both retained binding to PCGF1 and RING1B, components of PRC1.1, suggesting that the deletion of Bcor exon 4 does not compromise the function of PRC1.1 (Fig. 1 f) . Interestingly, the stabilization of BCL6, which may be induced by interaction with exogenous BCOR, was observed in cells transfected with full-length Bcor but not Bcor ΔE4 (Fig. 1 f) . Western blot analysis revealed that Bcor ΔE4/y BM c-Kit + progenitors and CD4 + CD8 + double-positive (DP) thymocytes had polycomb histone modifications (H2AK119ub1 and H3K27me3) at levels similar to WT ( Fig. 1 g) .
deletion of Bcor exon 4 impairs the repopulating capacity of hematopoietic stem cells
We first examined hematopoiesis in Bcor ΔE4/y mice. These mice exhibited leukopenia that was mainly attributed to impaired B lymphopoiesis (Fig. 2, a and b ). 6 mo after the deletion of Bcor exon 4, Bcor ΔE4/y mice showed reductions in the numbers of total BM, CD34 − LSK hematopoietic stem cells (HSCs), CD34 + LSK multipotent progenitors, spleen cells, thymocytes, and DP thymocytes (Fig. 2 , c-e). No significant difference was observed in the frequency of apoptotic cells between control and Bcor ΔE4/y LSK cells (Fig. 2 f) . Moreover, the proportion of HSPCs in the G 0 stage of the cell cycle did not change (Fig. 2 f) . To avoid the proliferative stress caused by BM transplantation, we also deleted Bcor exon 4 in primary Bcor fl/y mice. The mice showed hematopoietic phenotypes similar to those observed in BM transplant mice with the hematopoietic cell-specific deletion (not depicted). We then performed competitive repopulation assays using the same number of test cells and BM competitor cells and found that Bcor ΔE4/y BM cells were gradually outcompeted by WT BM cells in both peripheral blood (PB) and BM ( Fig. 2 g) , indicating the impaired repopulating capacity of Bcor ΔE4/y HSCs. We next purified CD34 − LSK HSCs and LSK HSPCs from the BM of WT and Bcor ΔE4/y mice and evaluated their proexon 4 by Cre recombinase. (c) Snapshots of RNA-seq signals at the Bcor gene locus in WT and Bcor ΔE4/y LSK cells isolated from recipient mice repopulated with Bcor ΔE4/y hematopoietic cells. The structure of the Bcor gene locus including relevant exons is indicated at the bottom. (d) Schematic representation of the BCOR ΔE4 protein. (e) BCOR ΔE4 protein in the thymus of Bcor ΔE4/y mice detected by Western blot analysis. WT and BCOR ΔE4 proteins are indicated by arrowheads. (f) BCOR ΔE4 retains the interaction with PCGF1 and RING1B, but not BCL6. 293T cells were cotransfected with plasmids encoding HA-tagged BCL6 and 3xFlag-tagged BCOR or BCOR ΔE4 , and immunoprecipitation was performed using an anti-Flag antibody. Western blot analysis was performed using anti-HA, anti-Flag, anti-PCGF1, or anti-RING1B antibodies. (g) Levels of global H2AK119ub1 in WT and Bcor ΔE4/y c-Kit + progenitors and DP thymocytes. Levels of H2AK119ub1 and H3K27me3 were normalized to the amount of H2A and H3, respectively, and are indicated relative to WT values. Representative data from at least two independent experiments are presented (b-g). (a) PB cell counts in WT and Bcor ΔE4/y mice. BM cells (5 × 10 6 ) from Bcor +/+ ;Cre-ERT and Bcor fl/y ;Cre-ERT CD45.2 mice were transplanted into lethally irradiated CD45.1 recipient mice. To delete Bcor exon 4, 100 µl tamoxifen (10 mg/ml) was intraperitoneally injected once a day for five consecutive days (at 4 wk posttransplantation). White blood cell (WBC), hemoglobin (Hb), and platelet (PLT) counts in the PB from WT (n = 4) and Bcor ΔE4/y (n = 12) mice after injection of tamoxifen are shown. Chimerism of CD45.2 + donor-derived liferative capacity in vitro. Although Bcor ΔE4/y HSCs showed significantly impaired cell growth under culture conditions that supported stem cell proliferation rather than differentiation (stem cell factor [SCF] and thrombopoietin [TPO]), Bcor ΔE4/y LSK HSPCs demonstrated moderately higher proliferation rates than WT under myeloid culture conditions (SCF+TPO+IL-3+GM-CSF; Fig. 2 h) , as reported previously for mice lacking Bcor exons 9 and 10 (Cao et al., 2016) . However, a serial methylcellulose replating colony assay did not show any enhancement in the serial replating capacity of Bcor ΔE4/y LSK cells (not depicted). These results indicate that the deletion of Bcor exon 4 compromises the repopulation capacity of HSCs both in vitro and in vivo, but not the proliferation and differentiation of hematopoietic progenitor cells.
deletion of Bcor exon 4 induces acute t-cell lymphoblastic leukemia
During an observation period of 300 d after the deletion of Bcor exon 4, 50% of Bcor ΔE4/y mice developed lethal acute T-cell lymphoblastic leukemia (T-ALL), whereas only one mouse developed B-ALL/lymphoma ( Fig. 3 a) . Moribund mice with T-ALL showed expansion of lymphoblasts, which were mostly DP or CD8 single-positive (SP; Fig. 3 , a-c and e). T-ALL cells were also detected in the PB, BM, thymus, and spleen to varying degrees ( Fig. 3 , b-e). All the T-ALL mice showed high chimerism of donor-derived cells (PB, 89.0 ± 4.6%; BM, 92.3 ± 4.3%; thymus, 98.8 ± 0.5%; and spleen, 97.4 ± 0.8%; n = 8-9). Most T-ALL involved the thymus, but 20% had no or minimal involvement of the thymus, suggesting BM origin of the disease. It was previously reported that loss of p53 induces the transformation of thymocytes, leading to the development of thymic T cell lymphoma characterized by the expansion of DP or CD8 SP lymphoblasts in mice (Donehower et al., 1992; Jacks et al., 1994) , and promotes transformation of cells with insufficient tumor suppressor functions (Jonkers et al., 2001; Celeste et al., 2003) . To test whether the loss of p53 accelerates leukemogenesis in Bcor ΔE4/y mice, we generated Bcor ΔE4/y p53 −/− mutants. Although all p53 −/− mice developed thymic T cell lymphoma, Bcor ΔE4/y p53 −/− mice developed T-ALL (60%) in addition to thymic T cell lymphoma (40%; Fig. 3 f) . Bcor ΔE4/y p53 −/− T-ALL showed phenotypes that were similar to those of Bcor ΔE4/y T-ALL (not depicted), albeit with markedly earlier onset (Fig. 3 , a and f). Although Bcor ΔE4 did not accelerate the development of thymic T cell lymphoma induced by the loss of p53, these results suggest that Bcor ΔE4 and inactive p53 alleles cooperate in the development of T-ALL in mice.
Myc is activated in Bcor ΔE4/y dP thymocytes and t-ALL
To elucidate the molecular mechanisms responsible for Bcor ΔE4/y T-ALL, we performed RNA sequence analysis of Bcor ΔE4/y DP leukemic blasts from the thymus of moribund mice (T-ALL no. 1) and WT DP thymocytes. Gene set enrichment analysis (GSEA) revealed the stronger enrichment of MYC target genes in Bcor ΔE4/y DP leukemic blasts than in WT DP thymocytes ( Fig. 4 a) . Myc is one of the potent oncogenes implicated in T-ALL (Belver and Ferrando, 2016) . It plays an important role in the control of cell growth downstream of NOT CH1 and pre-TCR signaling during early T cell development. NOT CH1 directly binds to a long-range distal Myc enhancer and activates Myc, which is crucial for T cell development and also the initiation and maintenance of NOT CH-dependent T-ALL (Yashiro-Ohtani et al., 2014; Herranz et al., 2015) . Although Myc is completely transcriptionally repressed in DP thymocytes that lose proliferative capacity, it was strongly up-regulated in Bcor ΔE4/y DP leukemic blasts (T-ALL no. 1; Fig. 4 b) and DP and CD8 SP blasts from T-ALL nos. 2 and 3, respectively (not depicted).
We then examined whether the active NOT CH1 pathway is involved in this process. Although NOT CH1 target gene sets were not significantly enriched in Bcor ΔE4/y T-ALL in GSEA (not depicted), many of the representative direct targets of NOT CH1 were up-regulated in Bcor ΔE4/y T-ALL in addition to Myc, such as Hes1, Ptcra, Ccnd1, Skp2, and Il7r ( Fig. 4 c) , suggesting that NOT CH1 signaling is augmented in Bcor ΔE4/y T-ALL. Sanger sequencing of exons 26-28 and 34 of Notch1, in which the majority of activating NOT CH1 mutations are found in human T-ALL, revealed a mutation in exon 34 in one of five T-ALLs (T-ALL no. 1; Fig. 4 d) . This mutation caused frameshift, which resulted in truncation of the PEST domain in the C-terminal region of the protein. We also found Notch1 deletions in two of five T-ALLs (T-ALL nos. 3 and 4), which remove exon 1 and the cells is indicated at right. (b) Proportions of myeloid cells (My; Mac-1 + and/or Gr-1 + ), B220 + B cells, and CD4 + or CD8 + T cells among CD45.2 + donor-derived hematopoietic cells and their absolute numbers in the PB from WT (n = 7) and Bcor ΔE4/y (n = 17) mice 4 mo after the injection of tamoxifen. (c) Absolute numbers of total BM cells, CD34 − LSK HSCs, and CD34 + LSK HPCs in a unilateral pair of femur and tibia 6 mo after the injection of tamoxifen (n = 4). (d and e) Absolute numbers of total spleen cells (d) and total thymocytes and double-negative, DP, CD4 SP, and CD8 SP thymocytes (e) 6 mo after the injection of tamoxifen (n = 4). CD45.1 + host and CD45.2 + donor-derived hematopoietic cells are indicated in c-e. (f) Proportion of apoptotic cells in the LSK fraction of BM and pyronin Y − G 0 cells in CD34 − LSK HSCs and CD34 + LSK HPCs 3 mo after the injection of tamoxifen (n = 3). (g) Competitive repopulating capacity of Bcor ΔE4/y hematopoietic cells. CD45.2 BM cells (2 × 10 6 ) from Bcor +/y ;Cre-ERT and Bcor fl/y ;Cre-ERT mice were transplanted into lethally irradiated CD45.1 recipient mice along with the same number of CD45.1 WT BM cells. Bcor exon 4 was deleted by injecting tamoxifen (at 4 wk posttransplantation). The chimerism of CD45.2 donor cells in the PB was monitored monthly, whereas that in the BM was examined 6 mo after the injection of tamoxifen (n = 4). (h) Growth of WT and Bcor ΔE4/y CD34 − LSK HSCs and LSK HSPCs in culture. HSCs and HSPCs were cultured in triplicate under stem cell-supporting culture conditions (SCF+TPO) and myeloid cell culture conditions (SCF+TPO+IL-3+GM-CSF), respectively. Data are shown as the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by Student's t test; N.S., not significant. Representative data from three independent experiments are presented (a-h). T-ALL mouse. Chimerism of donor-derived cells is indicated in parentheses. (d) PB counts and spleen and thymus weights in moribund Bcor ΔE4/y T-ALL mice and WT and Bcor ΔE4/y mice 300 d after the injection of tamoxifen (PB: WT, n = 3; Bcor ΔE4/y , n = 4; Bcor ΔE4/y T-ALL, n = 11; thymus: WT, n = 6; Bcor ΔE4/y , n = 9; Bcor ΔE4/y T-ALL, n = 10; spleen: WT, n = 6; Bcor ΔE4/y , n = 9; Bcor ΔE4/y T-ALL, n = 10). Bars in scatter diagrams indicate median values. *, P < 0.05; **, P < 0.01; proximal promoter ( Fig. S1 a) , leading to ligand-independent NOT CH1 activation (type 1 deletions; Ashworth et al., 2010) . None of the five T-ALLs had activating Notch1 transcripts, in which exon 1 is spliced out of frame to 3′ Notch1 exons (type 2 deletions; Fig. S1 b; Ashworth et al., 2010) . Western blotting for activated NOT CH1 revealed accumulation of cleaved NOT CH1 in CD8 SP and CD4 SP T-ALL cells from the spleens of T-ALL nos. 4 and 5, respectively ( Fig. 4 e) . Correspondingly, immunohistochemical analysis of the spleen of T-ALL no. 4 showed nuclear accumulation of cleaved NOT CH1 (Fig. S2 ). Finally, we treated leukemic cells (T-ALL no. 4) with N-[N-(3,5-difluorophenacetyl)l-alanyl]-S-phenylglycine t-butyl ester (DAPT), a γ-secretase inhibitor, and confirmed marked inhibition of cell growth in culture ( Fig. 4 f) . All these findings, which are summarized in Fig. S1 b, suggest that BCOR ΔE4 collaborates with active NOT CH1 to induce T-ALL.
During the differentiation of T lymphocytes in the thymus, Bcl6 is expressed in a manner that is reciprocal to Myc. Bcl6 is turned on in DP thymocytes in which Myc is shut off. In contrast, Bcor is expressed throughout differentiation ( Fig. 4 g) . We generated Bcl6 Δ/Δ mice reconstituted with Bcl6 fl/fl ;Cre-ERT BM cells followed by treatment with tamoxifen. The Bcl6 Δ mutant allele lacks exons 7-9, which encode the C-terminal zinc finger domains ZF1 to ZF5. The resultant protein cannot bind to DNA (Kaji et al., 2012) . RNA sequence analyses of DP thymocytes from Bcor ΔE4/y and Bcl6 Δ/Δ mice demonstrated significantly overlapping genes derepressed from those in WT, including Myc ( Fig. 4 h and Table S1 a). Myc was moderately up-regulated in both Bcor ΔE4/y and Bcl6 Δ/Δ DP thymocytes, albeit at lower levels than those in Bcor ΔE4/y T-ALL DP cells (Fig. 4 i) . GSEA revealed that the MYC target gene signature was positively enriched in Bcor ΔE4/y and Bcl6 Δ/Δ DP thymocytes (normalized enrichment score [NES] 1.66, nominal p-value [NOM] 0, and false discovery rate [FDR] 0.3; NES 2.06, NOM 0, and FDR 0, respectively).
We next purified CD4CD8 double-negative 1 (DN1) and DN2 thymocytes from Bcor ΔE4/y and Bcl6 Δ/Δ thymocytes and cultured them on TSt-4/DLL stromal cells expressing the NOT CH ligand, delta-like 1 (DLL1). Bcor ΔE4/y and Bcl6 Δ/Δ DN1/2 thymocytes showed higher proliferative rates under conditions that support thymocyte proliferation (Fig. 4 j) . Furthermore, under conditions that promote thymocyte differentiation, Bcor ΔE4/y and Bcl6 Δ/Δ thymocytes preferentially differentiated into CD8 SP thymocytes (Fig. 4 k) . These differentiation profiles of Bcor ΔE4/y and Bcl6 Δ/Δ thymocytes correlated well with that of Bcor ΔE4/y T-ALL cells, which preferentially showed the DP to CD8 SP phenotype.
Bcor targets Myc and other not cH1 targets in dP thymocytes
To identify BCOR targets in thymocytes, we performed a chromatin immunoprecipitation/DNA sequencing (ChIP-seq) analysis of BCOR using total thymocytes containing DP thymocytes as the major cell population. We detected 2,509 significant binding peaks of BCOR, the majority of which were located on the promoter region around the transcriptional start site (TSS; TSS ± 2.0 kb; Fig. 5 a and Table S1 b). Mapping of NOT CH1 peaks detected in T-ALL cells (Yashiro-Ohtani et al., 2014) revealed that a large number of BCOR peaks were located in close proximity to NOT CH1 peaks (±1.0 kb) at the promoter regions but not in the intergenic regions that contain enhancer elements (Fig. 5 a) . One of the representative NOT CH targets, Myc, was identified as a BCOR target in DP thymocytes (Fig. 5,  a and b) . A manual ChIP analysis confirmed the binding of BCOR to the Myc promoter ( Fig. 5 c) . BCL6 has also been reported to transcriptionally repress Myc in pre-BII cells in which Bcl6 is strongly up-regulated downstream of the pre-B cell receptor signal (Nahar et al., 2011) . Interestingly, BCOR appeared to reside on the Myc promoter in close proximity to NOT CH1 detected in T-ALL cells (Fig. 5 b) , but BCOR did not bind to the long-range distal Myc enhancer, which binds NOT CH complexes and physically interacts with the Myc promoter in T-ALL cells (Fig. 5 a; Yashiro-Ohtani et al., 2014; Herranz et al., 2015) . Further comparisons of the binding sites of BCOR in DP thymocytes and NOT CH1 in DP T-ALL cells (Yashiro-Ohtani et al., 2014) revealed that a large number of gene promoters had both BCOR and NOT CH1 peaks in close proximity (≤1.0 kb; Fig. 5, a and  d ), suggesting that BCOR and NOT CH regulate many genes reciprocally in the thymocytes including the representative NOT CH1 targets Myc and Hes1 (Fig. 5, b and d; and Table S1 c). These results suggest that BCOR antagonizes the transcriptional activation of T-ALL-related oncogenes by NOT CH1. However, most genes bound by BCOR at their promoters were not significantly derepressed in Bcor ΔE4/y DP thymocytes ( Fig. 5 e and Table S1 c), indicating that the loss of BCOR binding to BCL6 has minimal impact on the transcription of BCOR targets in a physiological setting in T lymphocytes. BCL6 may function as a repressor by recruiting histone deacetylases SMRT and NCOR, even in the absence of BCOR. Furthermore, the BCOR ΔE4/y protein stayed at nearly half of the WT BCOR targets in Bcor ΔE4/y thymocytes (Fig. 5, b and f; and Table S1, c and d), suggesting that the majority of BCOR is recruited to its target gene loci independently of physical binding to BCL6, possibly as a component of PRC1.1. Because global levels of the polycomb histone marks, H2Aub1 and H3K27me3, did not change ***, P < 0.001 by Student's t test; N.S., not significant. in Bcor ΔE4/y thymocytes (Fig. 1 g) , BCOR target genes in Bcor ΔE4/y thymocytes may still remain under the control of repressive polycomb histone modifications.
In this study, we provide the first evidence of a tumor suppressor function for BCOR in T-lymphocytes in vivo. Loss-of-function mutations in BCOR have been identified in myeloid malignancies. Furthermore, recent studies also identified BCOR mutations in lymphoid malignancies, such as extranodal NK/T cell lymphoma (21-32%) and chronic lymphocyte leukemia (2.2%; Landau et al., 2015; Lee et al., 2015; Dobashi et al., 2016) . Although BCOR mutations are detected in a significant portion (5-8%) of patients with T cell prolymphocytic leukemia, an aggressive neoplasm of mature T lymphocytes (Kiel et al., 2014; Stengel et al., 2016) , they are not common in patients with pediatric T-ALL (1.2%; Seki et al., 2017) . Our results indicate that the part of BCOR encoded by exon 4 mediates a tumor suppressor function in T lymphocytes. In germinal center B cells, BCOR functions as a corepressor of BCL6 in the context of a PRC1 complex. EZH2-containing PRC2 and BCL6 cooperate to assemble BCL6-BCOR-PRC1.1-PRC2 repressive complexes to promote lymphomagenesis (Béguelin et al., 2016) . In contrast, our results indicate a tumor suppressor function for BCOR in T lymphocytes. Nevertheless, it is important to note that many of the components of PRC2 are inactivated by somatic gene mutations in T lymphocytes (Ntziachristos et al., 2012; Zhang et al., 2012b; Kiel et al., 2014; Stengel et al., 2016) . These findings suggest that BCL6 cooperates with the BCOR-containing PRC1 in T lymphocytes in a manner similar to B lymphocytes, but targets different genes. In this regard, it would be intriguing to test whether the deletion of Bcl6 or the genes encoding other components of the BCOR-containing PRC1 also induces T-ALL in mice.
In the present study, the results of ChIP-seq analysis on thymocytes revealed that BCOR targets a significant portion of NOT CH1 targets detected in T-ALL cell lines, including Myc and Hes1. These results suggest that BCOR counteracts the oncogenic active NOT CH to restrain transformation. Therefore, the loss of BCOR may potentiate the transactivating ability of active NOT CH, thereby promoting the development of T-ALL. Indeed, BCOR ΔE4 appeared to collaborate with active NOT CH1 to induce T-ALL. Collectively, our results suggest that BCL6-BCOR-PRC1.1-PRC2 repressive complexes all collaborate to restrain the excessive activation of NOT CH1 target genes in thymocytes.
MAtErIALs And MEtHods Mice and generation of hematopoietic chimeras
The conditional Bcor allele (Bcor fl ), which contains LoxP sites flanking Bcor exon 4 containing the BCL6 binding domain, was generated by homologous recombination using R1 embryonic stem cells according to a conventional protocol. Bcor fl mice were backcrossed at least six times onto a C57BL/6 (CD45.2) background. Bcl6 and p53 conditional knockout mice (Bcl6 fl/fl and p53 fl/fl , respectively) have been described (Jonkers et al., 2001; Kaji et al., 2012) . In the conditional deletion of Bcor and Bcl6, mice were crossed with Rosa26::Cre-ERT mice (TaconicArtemis). To generate hematopoietic chimeras, we transplanted WT, Bcor fl/y ;Cre-ERT, or Bcl6 fl/fl ;Cre-ERT BM cells into lethally irradiated CD45.1 + recipient mice and deleted Bcor or Bcl6 4 wk posttransplantation by intraperitoneally injecting 100 µl tamoxifen dissolved in corn oil at a concentration of 10 mg/ml for five consecutive days. Littermates were used as controls. C57BL/6 mice congenic for the Ly5 locus (CD45.1) were purchased from Sankyo-Lab Service. All animal experiments were performed in accordance with our institutional guideas the mean ± SD (n = 3). Representative data from two independent experiments are presented. (c) Scatter diagram showing RNA sequence data. Signal levels of RefSeq genes (RPKM+1 in log2) in Bcor ΔE4/y DP T-ALL cells and WT DP thymocytes are plotted. Light gray lines represent the boundaries for a twofold increase and twofold decrease. Representative direct target genes of NOT CH1 are shown as red dots. (d) Chromatogram traces showing a Notch1 mutation in exon 34 (T-ALL no. 1). The variant bases are listed underneath and indicated in gray boxes. (e) Cleaved NOT CH1 protein in T-ALL cells detected by Western blot analysis. Cleaved NOT CH1 proteins in human T-ALL cells (Jurkat) and BCOR ΔE4 T-ALL cells (CD8 SP and CD4 SP T-ALL cells from the spleens of T-ALL nos. 4 and 5, respectively) are indicated by arrowheads. Actin served as a loading control. Representative data from two independent experiments are presented. (f) In vitro proliferation of Bcor ΔE4/y T-ALL cells. CD8 SP T-ALL cells from the spleen of T-ALL no. 4 were cultured on TSt-4 stromal cells in the presence of a γ-secretase inhibitor DAPT. Data are presented as the mean ± SEM of triplicate cultures. Representative data from two independent experiments are presented. ***, P < 0.001 by Student's t test. (g) Quantitative RT-PCR analysis of Bcor and Bcl6 in various hematopoietic cell fractions. Hprt1 was used to normalize the amount of input RNA. Data are shown as the mean ± SD (n = 3). Representative data from two independent experiments are presented. (h) Venn diagram of RefSeq genes up-regulated in DP thymocytes from Bcor ΔE4/y and Bcl6 Δ/Δ mice 4 wk after the injection of tamoxifen (more than twofold relative to the WT control). The numbers of genes in each group are indicated. The overlap between the two gene sets is statistically significant (P < 1 × 10 −242 ). (i) Snapshots of RNA sequence signals at the Myc gene locus in WT, Bcor ΔE4/y , and Bcl6 Δ/Δ DP thymocytes and Bcor ΔE4/y DP T-ALL cells. The structure of the Myc gene locus is indicated at the bottom. (j) In vitro proliferation of Bcor ΔE4/y and Bcl6 Δ/Δ thymocytes. DN1/2 thymocytes from Bcor ΔE4/y and Bcl6 Δ/Δ mice were cultured on TSt-4/DLL stromal cells in the presence of 10 ng/ml SCF, Flt3L, and IL-7. Data are presented as the mean ± SEM of triplicate cultures. (k) In vitro differentiation of Bcor ΔE4/y and Bcl6 Δ/Δ thymocytes. Culture conditions in j were switched to differentiation conditions by reducing the cytokine concentration to 2 ng/ml on day 14 of culture, and cells were cultured for a further 7 d. Differentiation was evaluated by flow cytometric analyses. Representative CD4 and CD8 expression profiles are depicted. The proportions of CD4 + CD8 + , CD4 + CD8 − , and CD4 − CD8 + thymocytes are as follows: WT, 25.8 ± 1.0, 21.7 ± 0.6, and 9.1 ± 0.1; Bcor ΔE4/y , 17.1 ± 0.6, 4.1 ± 0.1, and 24.0 ± 0.2; and Bcl6 Δ/Δ , 14.1 ± 0.8, 7.2 ± 0.2, and 16.3 ± 0.5, respectively (n = 3). The proportions of CD4 SP and CD8 SP thymocytes are shown at right. **, P < 0.01; ***, P < 0.001 by Student's t test. Representative data from three independent experiments are presented (j and k).
lines for the use of laboratory animals and approved by the Review Board for Animal Experiments of Chiba University (approval ID 25-104).
Flow cytometry and antibodies
Monoclonal antibodies recognizing the following antigens were used in flow cytometry and cell sorting: CD45.2 (104), CD45.1(A20), Gr-1 (RB6-8C5), CD11b/ Mac-1 (M1/70), Ter-119, CD127/IL-7R (A7R34), B220 (RA3-6B2), CD4 (L3T4), CD8 (53-6.7), CD34 (RAM34), CD117/c-Kit (2B8), Sca-1 (D7), CD16/32/FcγRII-III (93), γδTCR (GL3), NK1.1 (PK136), CD11c (N418), CD25 (PC61; APC), and CD44 (IM7; PE). Monoclonal antibodies were purchased from BD, BioLegend, eBioscience, or Tonbo. In Annexin V staining, cells were suspended in 1× Annexin binding buffer (BD) and stained with FITC Annexin V (BD) according to the manufacturer's protocol. To analyze the cell-cycle status, cells were incubated with 1 µg/ml Pyronin Y (Sigma-Aldrich) at 37°C for 45 min. Dead cells were eliminated by staining with 1 µg/ ml propidium iodide (Sigma-Aldrich). All flow cytometric analyses and cell sorting were performed on FAC SAria III or FACS Canto II (BD).
Growth and differentiation assays CD34 − LSK HSCs were cultured in S-Clone SF-O3 (Sanko Junyaku) supplemented with 0.1% BSA, 50 µM 2-mercaptoethanol, 1% glutamine/penicillin/streptomycin, 20 ng/ ml SCF, and 20 ng/ml TPO (Peprotech). LSK HSPCs were cultured in the presence of 20 ng/ml SCF, TPO, IL-3, and GM-CSF (Peprotech). Using a biotinylated lineage mixture (Gr-1, Mac-1, Ter-119, B220, CD4, CD8α, γδTCR, CD3ε, CD11c, and NK1.1), CD25, and CD44, Lin − CD25 − CD44 + DN1 and Lin − CD25 + CD44 + DN2 thymocytes were sorted on FAC SAria III and then cultured on TSt-4/DLL stromal cells. SCF, and Flt3L (Peprotech) were added to cultures at concentrations of 10 ng/ml and 2 ng/ml for growth and differentiation assays, respectively. Primary T-ALL cells from (Yashiro-Ohtani et al., 2014) at the promoter region. The overlapping genes had BCOR and NOT CH1 peaks at their promoters in close proximity (≤1.0 kb). Representative NOT CH1 target genes are indicated. (e) Venn diagram of BCOR target genes at promoters and genes derepressed more than twofold in Bcor ΔE4/y DP thymocytes from WT DP thymocytes. Representative NOT CH1 target genes are indicated. (f) Venn diagram of the target genes of BCOR and BCOR ΔE4/y in WT and Bcor ΔE4/y thymocytes, respectively. Representative data from two independent experiments are presented (a-f). leukemic mice were cultured on TSt-4 stromal cells in the presence of DAPT (Calbiochem).
Quantitative rt-Pcr
Total RNA was extracted using an RNeasy Mini kit (Qiagen) and reverse-transcribed by the ThermoScript RT-PCR system (Invitrogen) with an oligo-dT primer. Real-time quantitative PCR was performed with a StepOnePlus Real-Time PCR System (Life Technologies) using FastStart Universal Probe Master (Roche Applied Science) and the indicated combinations of the Universal Probe Library (Roche Applied Science). All data are presented as relative expression levels normalized to Hprt expression. Primer sequences used were as follows: Bcor forward, 5′-ATG GCG ACG CTT CAA AAG-3′, reverse 5′-GGG CTC CAC TGG TAT CCAC-3′, probe 19; Bcl6 forward, 5′-CCC CAC AGC ATA CAG AGA TG-3′, reverse 5′-TTG CAG AAG AAG GTC CCA TT-3′, probe 3; Myc forward, 5′-CCT AGT GCT GCA TGA GGA GA-3′, reverse 5′-TCC ACA GAC ACC ACA TCA ATTT-3′, probe 77; and Hprt forward, 5′-TCT TCC TCA GAC CGC TTTT-3′, reverse 5′-CCT GGT TCA TCA TCG CTA ATC-3′, probe 95. rnA sequencing Total RNA was extracted using an RNeasy Plus Micro kit (Qiagen), and cDNA was synthesized using a SMA RT-Seq v4 Ultra Low Input RNA kit for Sequencing (Clontech). ds-cDNA was fragmented using S220 Focused ultrasonicator (Covaris), then cDNA libraries were generated using a NEBNext Ultra DNA Library Prep kit (New England Biolabs). Sequencing was performed using HiSeq1500 (Illumina) with a single-read sequencing length of 60 bp. TopHat (version 2.0.13; default parameters) was used to map the reads to the reference genome (UCSC/mm10 or UCSC/hg19) with annotation data from iGenomes (Illumina). Levels of gene expression were quantified using Cuffdiff (Cufflinks version 2.2.1; default parameters).
chIP assays and chIP-seq
In ChIP assays, total thymus cells were fixed with 1% PFA at 25°C for 10 min, lysed in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, pH 8.0, 1% NP-40 substitute, 0.5% sodium deoxycholate, and 0.1% SDS), and sonicated using a homogenizer (NR-50M; Micro-tec Co.). After centrifugation, supernatants were subjected to immunoprecipitation using an anti-BCOR antibody (Gearhart et al., 2006) . Sheep anti-rabbit IgG Dynabeads were used to capture the anti-BCOR antibody. In the ChIP assay, quantitative PCR was performed with an ABI StepOnePlus thermal cycler with SYBR Premix Ex Taq II (Takara Bio) and the following primers: −3033 from TSS forward, 5′-TCT CCC TCC CCT TTT TCA GT-3′, reverse 5′-TGG CGT GTC ATG AAA CAG AT-3′; −296 from TSS forward, 5′-CAG GGC AAG AAC ACA GTT CA-3′, reverse 5′-GCT CCG GGG TGT AAA CAG TA-3′; and 558 from TSS forward, 5′-GAG CTC CTC GAG CTG TTTG-3′, reverse 5′-ACA CAG GGA AAG ACC ACC AG-3′.
ChIP-seq libraries were prepared using a ThruPLEX DNA-seq kit (Rubicon Genomics). Bowtie2 (version 2.2.6; default parameters) was used to map the reads to the reference genome (UCSC/mm10 or UCSC/hg19). Peaks were called using MACS2 v2.1.0 with a q-value of <0.2 (BCOR) or <10 −10 (NOT CH1). ChIP peaks that overlapped with those of corresponding input (distance between centers <10 kb) were removed. Reads per million mapped reads (RPM) values of the sequenced reads were calculated every 1,000-bp bin, with a shifting size of 100 bp using Bedtools. To visualize with Integrative Genomics Viewer (Broad Institute), the RPM values of the immunoprecipitated samples were normalized by subtracting the RPM values of the input samples in each bin and converted to a Bigwig file using the Wigtobigwig tool. target sequencing of notch1 Targeted sequencing of Notch1 was performed using previously described primers (Mayle et al., 2015) .
Plasmids, Western blot analysis, and immunoprecipitation
3xFlag-mouse Bcor and 3xFlag-Bcor delta exon 4 were subcloned into the lentivirus vector, CSII-EF1-MCS-IRES-Venus. HA-mouse Bcl6 was subcloned into the pcDNA3 vector. To detect nonhistone proteins using Western blot analysis, lysates were prepared as follows to minimize the fragmentation of proteins by sonication. Cells were lysed in 0.1% NP-40 lysis buffer (300 mM NaCl) and centrifuged. The resulting supernatants were kept on ice (solution A). Pellets were resuspended in SDS sample buffer and sonicated using a Bioruptor (Cosmo Bio; solution B). Mixtures of solutions A and B were incubated at 95°C for 10 min. To detect histone proteins, cells were lysed in 2× SDS sample buffer, sonicated, and incubated at 95°C for 10 min. Proteins were separated by SDS-PAGE, transferred to a PVDF membrane, and detected by Western blotting using the following antibodies: anti-BCOR (Gearhart et al., 2006) , anti-BCL6 (sc-7388; Santa Cruz Biotechnology), anti-actin (clone C-4, SC-47778; Santa Cruz Biotechnology), anti-Flag (clone M2, F3165; Sigma-Aldrich), anti-HA (clone 3F10, 11867423001; Roche), anti-cleaved NOT CH1 (4147; Cell Signaling Technology), anti-PCGF1 (183499; Abcam), anti-RING1B (D139-3; MBL), anti-H2AK119ub (8240S; Cell Signaling Technology), and anti-histone H2A (ab18255; Abcam). Protein bands were detected with enhanced chemiluminescence reagent (Immobilon Western; Millipore). The sequential reprobing of membranes with antibodies was performed after the removal of primary and secondary antibodies from membranes in 0.2 M glycine-HCl buffer (pH 2.5) and/or the inactivation of HRP by 0.1% NaN 3 . In immunoprecipitation, cells were lysed in 0.1% NP-40 lysis buffer (300 mM NaCl) as above. The pellets were resuspended in 0.1% NP-40 lysis buffer (300 mM NaCl) and sonicated (solution C). Mixtures of solution C and supernatant kept on ice were diluted with 0.1% NP-40 lysis buffer (0 mM NaCl) until the final NaCl concentrations reached 150 mM. After centrifugation, the resulting supernatants were used as input lysates for immunoprecipitation, which was performed using anti-Flag M2 Affinity Gel (A2220; Sigma-Aldrich). Immunoprecipitated proteins were subjected to Western blot analysisas described above.
statistical analysis
Statistical tests were performed using GraphPad Prism version 5. The significance of differences was measured by a Student's t test. Data are shown as the mean ± SEM. Significance was taken at values of *, P < 0.05; **, P < 0.01; and ***, P < 0.001. deposition of data RNA-seq and ChIP-seq data were deposited in the DNA Data Bank of Japan (accession no. DRA005459).
online supplemental material
Fig. S1 provides data of Notch1 status in Bcor ΔE4/y T-ALL. Fig. S2 shows immunohistochemical data of active NOT CH1 in Bcor ΔE4/y T-ALL. Table S1 , included as a separate Excel file, lists genes up-regulated in Bcor ΔE4/y and Bcl6 Δ/Δ DP thymocytes, Bcor ChIP-seq peaks in DP thymocytes, Notch1 ChIP-seq peaks in DP T-ALL, and Bcor ΔE4 ChIP-seq peaks in DP thymocytes.
